Loading…
Oestrogen receptor low positive breast cancer: associations with prognosis
Purpose In this study of oestrogen receptor (ER) Low Positive breast cancers (BC) in three large cohorts of BC patients, we assess associations between levels of ER expression and tumour characteristics and prognosis. Methods Cases were stratified into patients unlikely to have received adjuvant the...
Saved in:
| Published in: | Breast cancer research and treatment 2023-10, Vol.201 (3), p.535-545 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c573t-3745e29938cb1e5f69f28f24a3d362688b46009bcfafadd1516f036520f290d43 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c573t-3745e29938cb1e5f69f28f24a3d362688b46009bcfafadd1516f036520f290d43 |
| container_end_page | 545 |
| container_issue | 3 |
| container_start_page | 535 |
| container_title | Breast cancer research and treatment |
| container_volume | 201 |
| creator | Skjervold, Anette H. Valla, Marit Bofin, Anna M. |
| description | Purpose
In this study of oestrogen receptor (ER) Low Positive breast cancers (BC) in three large cohorts of BC patients, we assess associations between levels of ER expression and tumour characteristics and prognosis.
Methods
Cases were stratified into patients unlikely to have received adjuvant therapy according to treatment guidelines at time of diagnosis (before 1995), and those who could have received adjuvant therapy (diagnosed in 1995 or later). ER status was divided into |
| doi_str_mv | 10.1007/s10549-023-07040-9 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10460703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A762581592</galeid><sourcerecordid>A762581592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-3745e29938cb1e5f69f28f24a3d362688b46009bcfafadd1516f036520f290d43</originalsourceid><addsrcrecordid>eNp9kl9rFTEQxYNY7LX6BXyQBUF82TpJdpONL1KK_0qhL_ocstnJvSl7kzXZbfHbm_bWtldE8hDI_M6ZyXAIeUXhmALI95lC26gaGK9BQgO1ekJWtJW8lozKp2QFVMhadCAOyfOcLwFASVDPyCGXjWCya1bk7ALznOIaQ5XQ4jTHVI3xuppi9rO_wqpPaPJcWRMspg-VyTlab2YfQ66u_byppqIOhc4vyIEzY8aXd_cR-fH50_fTr_X5xZdvpyfntS2jzXXp3SJTine2p9g6oRzrHGsMH7hgouv6RpRBe-uMM8NAWyoccNEycEzB0PAj8nHnOy39FgeLYU5m1FPyW5N-6Wi83q8Ev9HreKUpFGcJvDi8u3NI8edSFqC3PlscRxMwLlmzjivWSEqhoG_-Qi_jkkL5X6FaKYGqRj5QazOi9sHF0tjemOoTKVjb0VaxQh3_gypnwK23MaDz5X1P8PaRYINmnDc5jsvt9vdBtgNtijkndPfboKBvsqJ3WdElK_o2K1oV0evHe7yX_AlHAfgOyKUU1pge_v4f29_FY8gF</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857701947</pqid></control><display><type>article</type><title>Oestrogen receptor low positive breast cancer: associations with prognosis</title><source>Springer Nature</source><creator>Skjervold, Anette H. ; Valla, Marit ; Bofin, Anna M.</creator><creatorcontrib>Skjervold, Anette H. ; Valla, Marit ; Bofin, Anna M.</creatorcontrib><description>Purpose
In this study of oestrogen receptor (ER) Low Positive breast cancers (BC) in three large cohorts of BC patients, we assess associations between levels of ER expression and tumour characteristics and prognosis.
Methods
Cases were stratified into patients unlikely to have received adjuvant therapy according to treatment guidelines at time of diagnosis (before 1995), and those who could have received adjuvant therapy (diagnosed in 1995 or later). ER status was divided into < 1%; ≥ 1 < 10%; ≥ 10%. Results were correlated with time of diagnosis, histopathological grade, proliferation status, and molecular subtypes, using Pearson’s Chi-square test. For prognosis, hazard ratios and cumulative incidence of death from BC were used.
Results
Of the 1955 tumours, 65 (3.3%) were ER Low Positive (ER ≥ 1 < 10%). Overall, the highest proportion of ER Low Positive tumours was observed among Luminal B (HER2 +) subtype (9.4%) and grade 3 tumours (4.3%). The risk of death from BC was lower in ER Low Positive and ER ≥ 10% compared to ER-negative cases. Compared to patients diagnosed before 1995, women diagnosed in 1995 or later showed a higher proportion of ER Low Positive BCs, and their tumours were of smaller size, lower grade, and lower proliferative status. There was no significant difference in prognosis compared to those with ER ≥ 10% tumours.
Conclusion
Women with ER Low Positive tumours diagnosed in a time period when adjuvant therapy was available had tumours of smaller size, lower grade, and lower proliferative status, and similar prognosis to those with ER ≥ 10% compared to women diagnosed earlier.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-023-07040-9</identifier><identifier>PMID: 37462784</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers, Tumor - metabolism ; Breast cancer ; Breast Neoplasms - pathology ; Cancer ; Cancer research ; Diagnosis ; ErbB-2 protein ; Estrogen ; Estrogen receptors ; Female ; Humans ; Medicine ; Medicine & Public Health ; Oncology ; Oncology, Experimental ; Original Laboratory Investigation ; Prognosis ; Proportional Hazards Models ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Tumors</subject><ispartof>Breast cancer research and treatment, 2023-10, Vol.201 (3), p.535-545</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>COPYRIGHT 2023 Springer</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-3745e29938cb1e5f69f28f24a3d362688b46009bcfafadd1516f036520f290d43</citedby><cites>FETCH-LOGICAL-c573t-3745e29938cb1e5f69f28f24a3d362688b46009bcfafadd1516f036520f290d43</cites><orcidid>0000-0002-2278-7233</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37462784$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Skjervold, Anette H.</creatorcontrib><creatorcontrib>Valla, Marit</creatorcontrib><creatorcontrib>Bofin, Anna M.</creatorcontrib><title>Oestrogen receptor low positive breast cancer: associations with prognosis</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
In this study of oestrogen receptor (ER) Low Positive breast cancers (BC) in three large cohorts of BC patients, we assess associations between levels of ER expression and tumour characteristics and prognosis.
Methods
Cases were stratified into patients unlikely to have received adjuvant therapy according to treatment guidelines at time of diagnosis (before 1995), and those who could have received adjuvant therapy (diagnosed in 1995 or later). ER status was divided into < 1%; ≥ 1 < 10%; ≥ 10%. Results were correlated with time of diagnosis, histopathological grade, proliferation status, and molecular subtypes, using Pearson’s Chi-square test. For prognosis, hazard ratios and cumulative incidence of death from BC were used.
Results
Of the 1955 tumours, 65 (3.3%) were ER Low Positive (ER ≥ 1 < 10%). Overall, the highest proportion of ER Low Positive tumours was observed among Luminal B (HER2 +) subtype (9.4%) and grade 3 tumours (4.3%). The risk of death from BC was lower in ER Low Positive and ER ≥ 10% compared to ER-negative cases. Compared to patients diagnosed before 1995, women diagnosed in 1995 or later showed a higher proportion of ER Low Positive BCs, and their tumours were of smaller size, lower grade, and lower proliferative status. There was no significant difference in prognosis compared to those with ER ≥ 10% tumours.
Conclusion
Women with ER Low Positive tumours diagnosed in a time period when adjuvant therapy was available had tumours of smaller size, lower grade, and lower proliferative status, and similar prognosis to those with ER ≥ 10% compared to women diagnosed earlier.</description><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Diagnosis</subject><subject>ErbB-2 protein</subject><subject>Estrogen</subject><subject>Estrogen receptors</subject><subject>Female</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original Laboratory Investigation</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kl9rFTEQxYNY7LX6BXyQBUF82TpJdpONL1KK_0qhL_ocstnJvSl7kzXZbfHbm_bWtldE8hDI_M6ZyXAIeUXhmALI95lC26gaGK9BQgO1ekJWtJW8lozKp2QFVMhadCAOyfOcLwFASVDPyCGXjWCya1bk7ALznOIaQ5XQ4jTHVI3xuppi9rO_wqpPaPJcWRMspg-VyTlab2YfQ66u_byppqIOhc4vyIEzY8aXd_cR-fH50_fTr_X5xZdvpyfntS2jzXXp3SJTine2p9g6oRzrHGsMH7hgouv6RpRBe-uMM8NAWyoccNEycEzB0PAj8nHnOy39FgeLYU5m1FPyW5N-6Wi83q8Ev9HreKUpFGcJvDi8u3NI8edSFqC3PlscRxMwLlmzjivWSEqhoG_-Qi_jkkL5X6FaKYGqRj5QazOi9sHF0tjemOoTKVjb0VaxQh3_gypnwK23MaDz5X1P8PaRYINmnDc5jsvt9vdBtgNtijkndPfboKBvsqJ3WdElK_o2K1oV0evHe7yX_AlHAfgOyKUU1pge_v4f29_FY8gF</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Skjervold, Anette H.</creator><creator>Valla, Marit</creator><creator>Bofin, Anna M.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2278-7233</orcidid></search><sort><creationdate>20231001</creationdate><title>Oestrogen receptor low positive breast cancer: associations with prognosis</title><author>Skjervold, Anette H. ; Valla, Marit ; Bofin, Anna M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-3745e29938cb1e5f69f28f24a3d362688b46009bcfafadd1516f036520f290d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Diagnosis</topic><topic>ErbB-2 protein</topic><topic>Estrogen</topic><topic>Estrogen receptors</topic><topic>Female</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original Laboratory Investigation</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skjervold, Anette H.</creatorcontrib><creatorcontrib>Valla, Marit</creatorcontrib><creatorcontrib>Bofin, Anna M.</creatorcontrib><collection>Springer Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skjervold, Anette H.</au><au>Valla, Marit</au><au>Bofin, Anna M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oestrogen receptor low positive breast cancer: associations with prognosis</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>201</volume><issue>3</issue><spage>535</spage><epage>545</epage><pages>535-545</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
In this study of oestrogen receptor (ER) Low Positive breast cancers (BC) in three large cohorts of BC patients, we assess associations between levels of ER expression and tumour characteristics and prognosis.
Methods
Cases were stratified into patients unlikely to have received adjuvant therapy according to treatment guidelines at time of diagnosis (before 1995), and those who could have received adjuvant therapy (diagnosed in 1995 or later). ER status was divided into < 1%; ≥ 1 < 10%; ≥ 10%. Results were correlated with time of diagnosis, histopathological grade, proliferation status, and molecular subtypes, using Pearson’s Chi-square test. For prognosis, hazard ratios and cumulative incidence of death from BC were used.
Results
Of the 1955 tumours, 65 (3.3%) were ER Low Positive (ER ≥ 1 < 10%). Overall, the highest proportion of ER Low Positive tumours was observed among Luminal B (HER2 +) subtype (9.4%) and grade 3 tumours (4.3%). The risk of death from BC was lower in ER Low Positive and ER ≥ 10% compared to ER-negative cases. Compared to patients diagnosed before 1995, women diagnosed in 1995 or later showed a higher proportion of ER Low Positive BCs, and their tumours were of smaller size, lower grade, and lower proliferative status. There was no significant difference in prognosis compared to those with ER ≥ 10% tumours.
Conclusion
Women with ER Low Positive tumours diagnosed in a time period when adjuvant therapy was available had tumours of smaller size, lower grade, and lower proliferative status, and similar prognosis to those with ER ≥ 10% compared to women diagnosed earlier.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37462784</pmid><doi>10.1007/s10549-023-07040-9</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2278-7233</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2023-10, Vol.201 (3), p.535-545 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10460703 |
| source | Springer Nature |
| subjects | Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - pathology Cancer Cancer research Diagnosis ErbB-2 protein Estrogen Estrogen receptors Female Humans Medicine Medicine & Public Health Oncology Oncology, Experimental Original Laboratory Investigation Prognosis Proportional Hazards Models Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Tumors |
| title | Oestrogen receptor low positive breast cancer: associations with prognosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A25%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oestrogen%20receptor%20low%20positive%20breast%20cancer:%20associations%20with%20prognosis&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Skjervold,%20Anette%20H.&rft.date=2023-10-01&rft.volume=201&rft.issue=3&rft.spage=535&rft.epage=545&rft.pages=535-545&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-023-07040-9&rft_dat=%3Cgale_pubme%3EA762581592%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c573t-3745e29938cb1e5f69f28f24a3d362688b46009bcfafadd1516f036520f290d43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2857701947&rft_id=info:pmid/37462784&rft_galeid=A762581592&rfr_iscdi=true |